Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

Posted on by

CHENGDU, China, Feb. 7, 2025 /PRNewswire/ — KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the “NMPA”) of China has recently approved the supplemental New Drug Application (the “sNDA”) of Stapokibart (anti-IL-4Rα monoclonal antibody, trade…